Seeking to Repair its Rep, KaloBios Strikes Deal with Shkreli

Source: Wall Street Journal

Jul 08, 2016

A week after emerging from bankruptcy, KaloBios Pharmaceuticals reached an agreement with former CEO Martin Shkreli to limit his shareholder rights.

In the agreement with KaloBios, for 180 days following the company’s effective emergence from its chapter 11 proceedings, Mr. Shkreli may not sell his shares to any third party for less than $2.50 a share or a 10% discount to the prior two-week volume-weighted average price. Shkreli lost his right to nominate directors, and he and his affiliates are prohibited for two years from purchasing shares, seeking to control management or participating in any transactions pursued by the company. Additionally, KaloBios has right to buy any or all of Mr. Shkreli’s shares at the market discount price for 180 days after Aug. 30.

“This agreement is another step in the company’s pursuit of revitalizing its reputation,” said Chief Executive Cameron Durrant.

Read the WSJ article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments